|
1
|
Khong HT and Restifo NP: Natural selection
of tumor variants in the generation of ‘tumor escape’ phenotypes.
Nat Immunol. 3:999–1005. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garrido F, Ruiz-Cabello F and Aptsiauri N:
Rejection versus escape: The tumor MHC dilemma. Cancer Immunol
Immunother. 66:259–271. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reinis M: Immunotherapy of MHC class
I-deficient tumors. Future Oncol. 6:1577–1589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garrido F, Aptsiauri N, Doorduijn EM,
Garcia Lora AM and van Hall T: The urgent need to recover MHC class
I in cancers for effective immunotherapy. Curr Opin Immunol.
39:44–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smyth MJ, Ngiow SF, Ribas A and Teng MW:
Combination cancer immunotherapies tailored to the tumour
microenvironment. Nat Rev Clin Oncol. 13:143–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zappasodi R, Merghoub T and Wolchok JD:
Emerging concepts for immune checkpoint blockade-based combination
therapies. Cancer Cell. 33:581–598. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thoreau M, Penny HL, Tan K, Regnier F,
Weiss JM, Lee B, Johannes L, Dransart E, Le Bon A, Abastado JP, et
al: Vaccine-induced tumor regression requires a dynamic cooperation
between T cells and myeloid cells at the tumor site. Oncotarget.
6:27832–27846. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moynihan KD, Opel CF, Szeto GL, Tzeng A,
Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds
AM, et al: Eradication of large established tumors in mice by
combination immunotherapy that engages innate and adaptive immune
responses. Nat Med. 22:1402–1410. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grzelak A, Polakova I, Smahelova J,
Vackova J, Pekarcikova L, Tachezy R and Smahel M: Experimental
combined immunotherapy of tumours with major histocompatibility
complex class I downregulation. Int J Mol Sci. 19:E36932018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin KY, Guarnieri FG, Staveley-O'Carroll
KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of
established tumors with a novel vaccine that enhances major
histocompatibility class II presentation of tumor antigen. Cancer
Res. 56:21–26. 1996.PubMed/NCBI
|
|
12
|
Smahel M, Sima P, Ludvikova V, Marinov I,
Pokorna D and Vonka V: Immunisation with modified HPV16 E7 genes
against mouse oncogenic TC-1 cell sublines with downregulated
expression of MHC class I molecules. Vaccine. 21:1125–1136. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Smahel M, Sima P, Ludvikova V and Vonka V:
Modified HPV16 E7 genes as DNA vaccine against E7-containing
oncogenic cells. Virology. 281:231–238. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smahel M, Polakova I, Duskova M, Ludvikova
V and Kastankova I: The effect of helper epitopes and cellular
localization of an antigen on the outcome of gene gun DNA
immunization. Gene Ther. 21:225–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alexander J, Sidney J, Southwood S,
Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT and
Sette A: Development of high potency universal DR-restricted helper
epitopes by modification of high affinity DR-blocking peptides.
Immunity. 1:751–761. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaštánková I, Poláková I, Dušková M and
Šmahel M: Combined cancer immunotherapy against aurora kinase A. J
Immunother. 39:160–170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simova J, Indrova M, Bieblová J, Mikyskova
R, Bubeník J and Reinis M: Therapy for minimal residual tumor
disease: β-galactosylceramide inhibits the growth of recurrent
HPV16-associated neoplasms after surgery and chemotherapy. Int J
Cancer. 126:2997–3004. 2010.PubMed/NCBI
|
|
18
|
Movahedi K, Laoui D, Gysemans C, Baeten M,
Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De
Baetselier P and Van Ginderachter JA: Different tumor
microenvironments contain functionally distinct subsets of
macrophages derived from Ly6C(high) monocytes. Cancer Res.
70:5728–5739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mills CD and Ley K: M1 and M2 macrophages:
The chicken and the egg of immunity. J Innate Immun. 6:716–726.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bernal M, Ruiz-Cabello F, Concha A,
Paschen A and Garrido F: Implication of the β2-microglobulin gene
in the generation of tumor escape phenotypes. Cancer Immunol
Immunother. 61:1359–1371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zaretsky JM, Garcia-Diaz A, Shin DS,
Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY,
Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations
associated with acquired resistance to PD-1 blockade in melanoma. N
Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Das K, Eisel D, Lenkl C, Goyal A,
Diederichs S, Dickes E, Osen W and Eichmüller SB: Generation of
murine tumor cell lines deficient in MHC molecule surface
expression using the CRISPR/Cas9 system. PLoS One. 12:e01740772017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Potter TA, Boyer C, Verhulst AM, Golstein
P and Rajan TV: Expression of H-2Db on the cell surface in the
absence of detectable beta 2 microglobulin. J Exp Med. 160:317–322.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Allen H, Fraser J, Flyer D, Calvin S and
Flavell R: Beta 2-microglobulin is not required for cell surface
expression of the murine class I histocompatibility antigen H-2Db
or of a truncated H-2Db. Proc Natl Acad Sci USA. 83:7447–7451.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bix M and Raulet D: Functionally conformed
free class I heavy chains exist on the surface of beta 2
microglobulin negative cells. J Exp Med. 176:829–834. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marozzi A, Meneveri R, Bunone G, De Santis
C, Lopalco L, Beretta A, Agresti A, Siccardi AG, Della Valle G and
Ginelli E: Expression of β2m-free HLA class I heavy chains in
neuroblastoma cell lines. Scand J Immunol. 37:661–667. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim HS, Garcia J, Exley M, Johnson KW,
Balk SP and Blumberg RS: Biochemical characterization of CD1d
expression in the absence of beta2-microglobulin. J Biol Chem.
274:9289–9295. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang WC, Wu D, Xie Z, Zhau HE, Nomura T,
Zayzafoon M, Pohl J, Hsieh CL, Weitzmann MN, Farach-Carson MC and
Chung LW: Beta2-Microglobulin is a signaling and growth-promoting
factor for human prostate cancer bone metastasis. Cancer Res.
66:9108–9116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nomura T, Huang WC, Zhau HE, Wu D, Xie Z,
Mimata H, Zayzafoon M, Young AN, Marshall FF, Weitzmann MN and
Chung LW: Beta2-microglobulin promotes the growth of human renal
cell carcinoma through the activation of the protein cinase A,
Cyclic AMP–responsive element-binding protein, and vascular
endothelial growth factor axis. Clin Cancer Res. 12:7294–7305.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nomura T, Huang WC, Zhau HE, Josson S,
Mimata H and Chung LW: β2-Microglobulin-mediated signaling as a
target for cancer therapy. Anticancer Agents Med Chem. 14:343–352.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sneed RA, Stevenson AP and Stewart CC:
Quantitation of the host cell infiltration kinetics of the
nonimmunogenic colon 26 tumor by multiparameter flow cytometry. J
Leukoc Biol. 46:547–555. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kennedy BC, Maier LM, D'Amico R, Mandigo
CE, Fontana EJ, Waziri A, Assanah MC, Canoll P, Anderson RC,
Anderson DE and Bruce JN: Dynamics of central and peripheral
immunomodulation in a murine glioma model. BMC Immunol. 10:112009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bindea G, Mlecnik B, Tosolini M,
Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T,
Lafontaine L, Berger A, et al: Spatiotemporal dynamics of
intratumoral immune cells reveal the immune landscape in human
cancer. Immunity. 39:782–795. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng WF, Hung CF, Lin KY, Ling M, Juang
J, He L, Lin CT and Wu TC: CD8 + T cells, NK cells and IFN-gamma
are important for control of tumor with downregulated MHC class I
expression by DNA vaccination. Gene Ther. 10:1311–1320. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Indrová M, Símová J, Bieblová J, Bubeník J
and Reinis M: NK1.1+ cells are important for the development of
protective immunity against MHC I-deficient, HPV16-associated
tumours. Oncol Rep. 25:281–288. 2011.PubMed/NCBI
|
|
36
|
van der Sluis TC, Sluijter M, van Duikeren
S, West BL, Melief CJ, Arens R, van der Burg SH and van Hall T:
Therapeutic peptide vaccine-induced CD8 T cells strongly modulate
intratumoral macrophages required for tumor regression. Cancer
Immunol Res. 3:1042–1051. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Perea F, Bernal M, Sánchez-Palencia A,
Carretero J, Torres C, Bayarri C, Gómez-Morales M, Garrido F and
Ruiz-Cabello F: The absence of HLA class I expression in non-small
cell lung cancer correlates with the tumor tissue structure and the
pattern of T cell infiltration. Int J Cancer. 140:888–899. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aptsiauri N, Ruiz-Cabello F and Garrido F:
The transition from HLA-I positive to HLA-I negative primary
tumors: The road to escape from T-cell responses. Curr Opin
Immunol. 51:123–132. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ugurel S, Spassova I, Wohlfarth J, Drusio
C, Cherouny A, Melior A, Sucker A, Zimmer L, Ritter C, Schadendorf
D and Becker JC: MHC class-I downregulation in PD-1/PD-L1 inhibitor
refractory Merkel cell carcinoma and its potential reversal by
histone deacetylase inhibition: A case series. Cancer Immunol
Immunother. 68:983–990. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang S, Kohli K, Black RG, Yao L,
Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee
C, et al: Systemic interferon-γ increases MHC class I expression
and T-cell infiltration in cold tumors: Results of a phase 0
clinical trial. Cancer Immunol Res. 7:1237–1243. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Di Vito C, Mikulak J, Zaghi E, Pesce S,
Marcenaro E and Mavilio D: NK cells to cure cancer. Semin Immunol.
41:1012722019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wright SE, Rewers-Felkins KA, Chowdhury
NI, Ahmed J and Srivastava SK: Prevention of human adenocarcinoma
with CpG-ODN in a mouse model. Oncol Lett. 4:1061–1063. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Maimela NR, Liu S and Zhang Y: Fates of
CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J.
17:1–13. 2018. View Article : Google Scholar : PubMed/NCBI
|
